Why the study?
What are the most promising strategies to limit or prevent anthracycline-induced cardiotoxicity in children and adults?
What are the most promising strategies to limit or prevent anthracycline-induced cardiotoxicity in children and adults?
This review summarizes current strategies to prevent or limit anthracycline-induced cardiotoxicity, which could improve cancer survival and quality of life.
Answers are grounded in this paper and cite their sources.
May guide anthracycline cardiotoxicity prevention in practice; leaves open optimal strategies pending prospective trials.
Over the last 40 years, great progress has been made in treating childhood and adult cancers. However, this progress has come at an unforeseen cost, in the form of emerging long-term effects of anthracycline treatment. A major complication of anthracycline therapy is its adverse cardiovascular effects. If these cardiac complications could be reduced or prevented, higher doses of anthracyclines could potentially be used, thereby further increasing cancer cure rates. Moreover, as the incidence of cardiac toxicity resulting in congestive heart failure or even heart transplantation dropped, the quality and extent of life for cancer survivors would improve. We review the proposed mechanisms of action of anthracyclines and the consequences associated with anthracycline treatment in children and adults. We summarise the most promising current strategies to limit or prevent anthracycline-induced cardiotoxicity, as well as possible strategies to prevent existing cardiomyopathy from worsening.
No takes yet. Share an insight, caveat, or question.
Wouters et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: